MedTrace Logo

Cardiorespiratory Fitness in Children and Adolescents After Cancer Treatment.

NCT04765020 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-05-15

No results posted yet for this study

Summary

The POWER-study is a two-arm exercise intervention study for pediatric patients following acute cancer treatment. This clinical trial will investigate the effects of a 12-week moderate to high-intensity exercise program on cardiorespiratory fitness in children and adolescents beginning 6 weeks after completion of acute cancer treatment.

Conditions

  • All Types of Pediatric Cancer

Interventions

BEHAVIORAL

Experimental: moderate to high-intensity exercise

Four parts: 1. Initial consultation with recommendations for general physical activity, brochure with exercise recommendations 2. Once per week multi-modal group-based exercise (endurance, strength, mobility, coordination) 3. Once per week supervised multi-modal individual training session (endurance, strength, mobility, coordination). Intensity: 60-80% of max. HR 4. Activity trackers with individual movement goals that will be adjusted every two weeks

Sponsors & Collaborators

  • Helios Hospital Krefeld

    collaborator UNKNOWN

  • Oslo Centre for Biostatistics and Epidemiology

    collaborator UNKNOWN

  • University Hospital, Essen

    collaborator OTHER

  • Universität Duisburg-Essen

    lead OTHER

Principal Investigators

  • Miriam Götte, Phd · University Hospital, Essen

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
23 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-21
Primary Completion
2027-12-31
Completion
2028-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04765020 on ClinicalTrials.gov